Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study

被引:119
作者
Amin, Janaki [1 ]
Dore, Gregory J.
O'Connell, Dianne L.
Bartlett, Mark
Tracey, Elizabeth
Kaldor, John M.
Law, Matthew G.
机构
[1] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[2] NSW Canc Council, Sydney, NSW, Australia
[3] NSW Dept Hlth, Sydney, NSW, Australia
[4] Canc Inst New S Wales, Sydney, NSW, Australia
关键词
hepatitis B; hepatitis C; hepatocellular carcinoma; epidemiology; linkage; cancer;
D O I
10.1016/j.jhep.2006.02.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Risks of hepatocellular carcinoma (HCC) following hepatitis B and/or hepatitis C virus (HBVIHCV) infection are well known, those for other cancers are less well understood. The aim was to quantify the risk of cancers among persons diagnosed with HBV/HCV infections. Methods: The data from a cohort of 39109 HBV, 75834 HCV, and 2604 HBV/HCV co-infected persons notified to the State health department, 1990-2002, were probabilistically linked to the Cancer Registry and standardised incidence ratios (SIRs) for cancer were calculated. Results: The match rate for any cancer was 2.7%, 2.3% and 3.3% for HBV, HCV and HBV/HCV co-infected notifications. SIRs for HCC were 30.6 (95% CI 25.7-36.5), 22.7 (95% Cl 19.1-26.5) and 30.3 (95% CI 13.6-67.5), respectively. Increased risk was detected for Burkitt's lymphoma and HBV (SIR 12.9, 95% CI 5.4-30.9) and immunoproliferative malignancies following HCV (SIR 5.6, 95% CI 1.8-17.5). Conclusions: The risk of HCC in the infected cohort was 20-30 times greater than in the uninfected population with SIRs two to three times greater than those for the other HBVA-1CV infection associated cancers. The modest though significant risk of immunoproliferative malignancies associated with HCV infection is consistent with recent findings. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:197 / 203
页数:7
相关论文
共 58 条
[1]  
*AUTOMATCH, 1997, GEN REC LINK SYST
[2]  
BEASLEY RP, 1981, LANCET, V2, P1129
[3]  
Breslow N E, 1987, IARC Sci Publ, P1
[4]  
BRITTON WJ, 1985, AUST NZ J MED, V15, P641
[5]  
BRUIX J, 1989, LANCET, V2, P1004
[6]  
COLOMBO M, 1989, LANCET, V2, P1006
[7]  
Cote TR, 1997, INT J CANCER, V73, P645, DOI 10.1002/(SICI)1097-0215(19971127)73:5&lt
[8]  
645::AID-IJC6&gt
[9]  
3.0.CO
[10]  
2-X